The biggest gene-editing story of 2026 isn't a new editor. It's a form.

Nurse habit: I judge a therapy by what has to go right at 3am. So the 2026 story isn't CRISPR getting sharper. It's the FDA's February guidance on a "plausible mechanism" pathway: approve a platform, not a product, so each patient's edit rides on it. The boy at CHOP whose base editor was built for his one mutation is walking now. Wonderful, and unrepeatable: an army and a custom regulatory argument for ONE child. The bottleneck was never the scissors - every rare mutation is its own trial. The fix is a form. Unglamorous, and the first time I've watched this field make the maintenance schedule cheaper instead of the miracle bigger. But "plausible mechanism" means approving on the argument it ought to work. On my ward, that's where people get hurt. Where's the line?